Data from: Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)

  • Seonaidh Cotton (Creator)
  • Graham Devereux (Creator)
  • Hassan Abbas (Creator)
  • Andrew Briggs (Creator)
  • Karen Campbell (Creator)
  • Rekha Chaudhuri (Creator)
  • Gourab Choudhury (Creator)
  • Dana Dawson (Creator)
  • Anthony De Soyza (Creator)
  • Shona Fielding (Creator)
  • Simon Gompertz (Creator)
  • John Haughney (Queen Elizabeth University Hospital) (Creator)
  • Chim C Lang (Creator)
  • Amanda Lee (Creator)
  • Graeme MacLennan (Creator)
  • William MacNee (Creator)
  • Kirsty McCormack (Creator)
  • Nicola McMeekin (Creator)
  • Nicholas L Mills (Creator)
  • Alyn Morice (Creator)
  • John Norrie (Royal Edinburgh Hospital) (Creator)
  • Mark C. Petrie (Creator)
  • David Price (Creator)
  • Philip Short (Creator)
  • Jorgen Vestbo (Creator)
  • Paul Walker (Creator)
  • Jadwiga A Wedzicha (Creator)
  • Andrew Wilson (University of East Anglia, University of Leicester) (Creator)
  • Brian J Lipworth (Creator)



Abstract Background Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta blockers are well-established drugs widely used to treat cardiovascular conditions. Observational studies consistently report that beta blocker use in people with COPD is associated with a reduced risk of COPD exacerbations. The bisoprolol in COPD study (BICS) investigates whether adding bisoprolol to routine COPD treatment has clinical and cost-effective benefits. A sub-study will risk stratify participants for heart failure to investigate whether any beneficial effect of bisoprolol is restricted to those with unrecognised heart disease. Methods BICS is a pragmatic randomised parallel group double-blind placebo-controlled trial conducted in UK primary and secondary care sites. The major inclusion criteria are an established predominant respiratory diagnosis of COPD (post-bronchodilator FEV1
Date made available2022

Cite this